Budesonide
Budesonide is a **locally acting, highly potent glucocorticoid** (approximately 15 times more potent than prednisolone) with weak mineralocorticoid activity. * **Targeted Delivery**: Oral formulations are typically enteric-coated (e.g., Entocort EC®) to delay dissolution until the drug reaches the duodenum. This allows the medication to exert concentrated, topical anti-inflammatory action directly within the intestines. * **Reduced Systemic Effects**: While absorbed into the portal circulation, budesonide undergoes extensive **first-pass hepatic metabolism**. The liver clears the vast majority of the drug before it reaches systemic circulation, significantly reducing the risk of classic systemic steroid side effects (such as polyuria, polydipsia, and polyphagia). * **Clinical Utility**: Primarily used off-label in veterinary medicine for **Inflammatory Bowel Disease (IBD)** in dogs and cats that are either refractory to, or intolerant of, traditional systemic corticosteroids. * **Cost & Formulation**: Expense can be a limiting factor, and because human capsules are often too large for small veterinary patients, the drug frequently requires compounding into smaller dosage strengths.
กลไกการออกฤทธิ์: Budesonide diffuses across cell membranes and binds with high affinity to cytosolic **glucocorticoid receptors (GR)**. * The receptor-ligand complex translocates to the nucleus → binds to glucocorticoid response elements (GREs) on DNA → alters gene transcription. * **Anti-inflammatory pathway**: Induces the production of **lipocortin-1 (annexin-1)** → inhibits **phospholipase A2** → blocks the release of arachidonic acid from membrane phospholipids → decreases the synthesis of potent inflammatory mediators (prostaglandins and leukotrienes). * Despite its high first-pass metabolism, it still causes significant suppression of the **hypothalamic-pituitary-adrenal (HPA) axis**.
ขนาดยาตามชนิดสัตว์
- Inflammatory Bowel Disease (IBD) (Clinical Pearl) · 1 - 3 mg/m2 or 1 - 3 mg/dog · PO · q24h · Chronic management; taper to lowest effective dose · Do not crush or chew capsules.
- Inflammatory Bowel Disease (IBD) (Clinical Pearl) · 1 mg/cat · PO · q24h · Chronic management; taper to lowest effective dose · May be compounded if standard sizes are too large, though this alters the enteric coating.
- Feline Asthma (Clinical Pearl) · 100 - 400 µg (1-2 puffs) · Inhalation · q12h · Chronic management · Administer via a feline-specific spacer mask (e.g., AeroKat).
ขนาดยาเป็นข้อมูลอ้างอิงทางคลินิกสำหรับสัตวแพทย์ผู้มีใบอนุญาต โปรดตรวจสอบกับฉลากล่าสุดและผู้ป่วยแต่ละรายเสมอ
วิธีการให้ยา
ข้อห้ามใช้
- Hypersensitivity to budesonide
- Patients with active GI ulcers
- Active systemic infections
- Diabetes mellitus
- Cataracts
อาการไม่พึงประสงค์
- Steroid hepatopathy
- HPA-axis suppression
- Hyperadrenocorticism (rare, but risk increases with hepatic dysfunction)
อันตรกิริยาระหว่างยา
- CYP3A Inhibitors (e.g., ketoconazole, itraconazole, erythromycin) · May decrease the hepatic metabolism of budesonide, leading to increased systemic blood levels and a higher risk of glucocorticoid adverse effects.
- Antacids, H2-blockers, Proton Pump Inhibitors · May increase gastric pH, potentially causing premature dissolution of the enteric coating and reducing the drug's targeted efficacy in the intestines.
- Ketoconazole · Inhibits CYP3A4, significantly increasing systemic budesonide levels and risk of toxicity · major
- Itraconazole · Inhibits CYP3A4, increasing systemic budesonide levels · major
- Erythromycin · Inhibits CYP3A4, potentially increasing budesonide levels · moderate
- NSAIDs (e.g., Meloxicam, Carprofen) · Increased risk of gastrointestinal ulceration and bleeding · major
การติดตาม
- Resolution of clinical signs of IBD (vomiting, diarrhea, weight loss)
- Liver enzymes (ALP, ALT) for potential steroid hepatopathy
- Clinical signs of hyperadrenocorticism (PU/PD/PP, panting, alopecia)
การได้รับยาเกินขนาด
Acute oral overdoses are unlikely to be of much clinical concern, though massive overdoses may warrant gut evacuation. The lethal dose in mice is reported to be 200 mg/kg.
ข้อมูลอ้างอิงยาของ VetSheet มีไว้สำหรับสัตวแพทย์ผู้มีใบอนุญาตเพื่อช่วยในการตัดสินใจทางคลินิก ไม่ใช่สิ่งทดแทนการวินิจฉัยของผู้เชี่ยวชาญหรือฉลากล่าสุดของผู้ผลิต